A Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Subjects with Sickle Cell Disease
Administered By
Awarded By
Contributors
- Shah, Nirmish Ramesh Principal Investigator
Start/End
- May 17, 2017 - September 25, 2020